ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1668

Improving the Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis with a New Predictive Model Using the 10-Year Prospective Carre-Study

Alper M. van Sijl1, Inge A.M. van den Oever1, Mike J.L. Peters2, Vokko P. van Halm3, Alexandre E. Voskuyl4, Yvo M. Smulders5 and Mike T. Nurmohamed1, 1Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Internal medicine, VU University Medical Center, Amsterdam, Netherlands, 3Cardiology, Academic Medical Centre, Amsterdam, Netherlands, 4Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 5Internal Medicine, VU University Medical Center, Amsterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research III: Rheumatic Diseases and Cardiovascular Disease and Risk Assessment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is associated with an increased cardiovascular (CV) risk. Traditional CV risk factors do not fully explain the increased CV risk and prediction of future CV disease in RA by CV risk estimates (Framingham and Reynolds) has shown to be inadequate. The present study investigated whether future CV disease in RA can be accurately predicted by demographic factors, CV risk factors, RA-related factors, CV risk estimates and surrogate markers of CV disease, or a combination of all.

Methods: 10-year incidence rate of CV disease was determined in a prospective cohort of 353 RA-patients. CV risk factors, RA-related factors and surrogate markers of CV disease were assessed at baseline. Predictive models of separate variables or in combinations were created using stepwise backward logistic regression analyses and areas under the curve (AUC) were calculated using receiver operating curves (ROC) analyses.

Results: After 10 years, there were 58 events over 2361 patient years of follow-up. CV disease incidence was 16.4%, while 10-year CV risk estimates with SCORE and Framingham underestimated this risk with 5.9% and 13.0%, respectively. From ROC analyses, a model was created which seemed to predict CV disease incidence better than the already available 10-year CV risk estimates (AUC 0.801 vs. 0.712, respectively). For RA patients without prior CV disease, the model consisted of  age, gender, use of statins and prednisone, body-mass index, diastolic blood pressure, LDL cholesterol, total cholesterol to HDL-cholesterol ratio, C-reactive protein, HAQ and ESR.

Conclusion: 10-year CV risk estimates did not accurately predict the actual CV risk in a population of RA patients. A combined model of demographic factors, CV risk factors and RA related factors more accurately predicted the actual CV risk. Future studies should corroborate these findings and consider whether modification of pre-existing risk models will improve the CV risk assessment in RA patients.

Table 1. Comparison of incident cardiovascular (CV) disease with 10-year CV risk estimates

 

All RA-patients (n=349)

Prior CV disease excluded (n=295)

Follow-up characteristics

Total follow-up, years

2361

2042

Cases of CV disease, number

58

41

Incidence rates / 1.000 patient years

Total CV disease

24.6

20.1

CV mortality

3.4

3.4

Coronary artery disease

14.4

12.2

Cerebrovascular disease

6.3

4.9

Peripheral arterial disease

4.7

2.9

Observed and predicted 10-year CV disease incidence

Observed 10-year CV disease incidence, %

16.4

13.9

Predicted 10-year CV disease risk at   baseline according to SCORE-formula, %

5.9

4.9

Predicted 10-year CV disease risk at baseline according to Framingham-formula, %

13.0

11.0

Figure 1. ROC curve for the prediction of incident CV disease using a model consisting of demographical factors, CV risk factors and RA related factors



Disclosure:

A. M. van Sijl,
None;

I. A. M. van den Oever,
None;

M. J. L. Peters,
None;

V. P. van Halm,
None;

A. E. Voskuyl,
None;

Y. M. Smulders,
None;

M. T. Nurmohamed,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-the-accuracy-of-cardiovascular-risk-prediction-in-rheumatoid-arthritis-with-a-new-predictive-model-using-the-10-year-prospective-carre-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology